Wednesday - October 2, 2013 POSTER TOURS 5:15 PM – 6:45 PM Exhibit Hall (220C)
Presenters of featured posters will be present during poster tours to explain their work. Tours take place at the end of the day onTuesday and Wednesday. Tour sign-up required (see sheets in front of main entrance to Exhibit Hall at 220D). Meeting point at firstposter of tour at 5:15 PM. Poster Tour W1 Matthew Farrer (USA) Calmodulin regulation of L-type calcium channels in SNc DA neuron culture Dietary administration of paraquat for 13 weeks does not result in a loss ofdopaminergic neurones in the substantia nigra of mice Role of MAPT variation in Parkinsonian disorders Exome sequencing of Norwegian families with PD reveals novel gene mutations Household organophosphorus pesticide use and Parkinson’s disease Exploring the impact of Parkinson disease (PD) susceptibility loci in olderpersons without PD The complex interaction of LRRK2 with the cytoskeleton Poster Tour W2 Ted Dawson Protein misfolding cyclic amplification (PMCA) as an alpha-synuclein anti-aggregation drug-screening tool Smoking and Parkinson’s disease: nicotine binds to alpha-synuclein and causeslarge conformational changes which may prevent it from misfolding 14-3-3 chaperone protein modulates alpha-Synuclein aggregation and toxicity The role of intramolecular interactions in parkin activation in vivo Mutant LRRK2 expression induces calcium dysregulation and dendritic mitophagy High Cortical LB burden and ABeta pathology in Lewy Body Dementia and Parkinson’s disease Dementia Tau oligomers as novel therapeutic target for PD and neurodegenerativesynucleinopathies Poster Tour W3 Etienne Hirsch Neuroprotection and neurorescue properties of Sitagliptin in 6-hydroxydopaminerodent model of Parkinson’s disease The effect of a chronic treatment with MPEP, an mGlu5 receptor antagonist, onbrain basal ganglia D1/D2 receptors, preproenkephalin/preprodynorphin mRNAlevels and ERK/Akt signaling pathways in de novo parkinsonian monkeys A functional magnetic resonance imaging approach towards understanding thecircuit-level effects of deep brain stimulation Quantitative evaluation of hypokinesia in Parkinson’s disease using sensor gloves Dose-dependent therapeutic effects of FK506 on dopaminergic neurodegenerationand neuroinflammation in a viral vector-based alpha-synuclein rat model for Parkinson’s disease Unilateral 6-OHDA lesion and Dopa administration in Nur77 knockout rats revealan important role of this transcription factor in Parkinson’s disease and itstreatment Selective knockout of the vesicular GABA transporter (VGAT) in the motor cortexcompletely protects against MPTP-induced lesioning in mice Poster Tour W4 Alice Templin Tai Chi, zumba, drumming and golf: an integrative approach to promote PDwellness Effects of resistance training on bradykinesia, functional performance anddisease severity in individuals with Parkinson’s disease Development of a community-based Nordic walking program for persons with Parkinson’s disease Comparative biomechanics from ice skating and regular terrain locomotion amongstpeople living with Parkinson’s disease School “Health” in the lives of patients with Parkinson’s disease Shared decision making in current treatment choice in advanced Parkinson’s disease Equal options; shared decision? Development of a decision aid for treatmentchoice in advanced Parkinson’s disease POSTER TOURS Poster Tour W5 Anne-Louise Lafontaine Developing a network of interdisciplinary Parkinson’s rehabilitation teams in nontraditional settings: providing high-quality treatment to populations inunderserved settings The relationship between patient age and resource utilization among newly diagnosed Parkinson’s disease patients Our experience developing a service for in-patients with Parkinson’s Does a specialist Parkinson’s unit improve outcomes for hospitalised Parkinson’spatients? Multidisciplinary care in professional networks for Parkinson’s disease Poster Tour W6 Michel Panisset Antipsychotic efficacy and motor tolerability in a phase III placebo-controlledstudy of pimavanserin in patients with Parkinson’s disease psychosis (ACP-103-020) Gender differences in non-motor symptoms in early, drug naïve Parkinson’s disease Motor, cognitive and affective characteristics of new-fallers compared tonon-fallers in an incident cohort of Parkinson’s disease Gait predicts decline in attention over 18 months in an incident cohort of Parkinson’s disease The Relation between Obsessive Compulsive Behaviors and PARKIN Genotype The clinical features of asymptomatic, first degree relatives of Ashkenazi Jewish Parkinson patients, carriers of the G2019S mutation in the LRRK2 gene Poster Tour W7 Daniel Weintraub Personality and depression: Factors that influence reported quality of life among PD patients Impact of Parkinson’s disease on social role function: Multi-faceted disability A new paradigm in neuropsychological assessment: Motor Imagery. A pilot Study with Parkinson’s disease patients Vitamin D in Parkinson’s disease High intensity exercise improves skeletal muscle mitochondrial functioncorresponding with reduced fatigability in Parkinson’s Treatment of obstructive sleep apnea with continuous positive airway pressureimproves non-motor symptoms in Parkinson’s disease patients Focus Group and Quantitative Assessment of Sleep and Fatigue in Patients with Parkinson’s Disease The Roles of Dorsal and Ventral Striatum in Stimulus-Response Learning: Implications for Parkinson’s Disease Poster Tour W8 Anthony Lang Changes in troublesome dyskinesia and its relationship with dose in advanced Parkinson’s disease patients treated with levodopa-carbidopa intestinal gelinfusion Taq1A polymorphism improves Dopamine Agonist therapeutic response in Parkinson’s Disease Effects of levodopa on gait variabiolity of backward walking in Parkinson’s disease Safety analyses from open-label clinical trials of levodopa-carbidopa intestinalgel in patients with advanced Parkinson’s disease: Events not related to deviceor procedure Effective treatment of Parkinson tremor using kinematics to optimize Botulinumneurotoxin type A injection Pharmaceutical Quality of Seven generic Levodopa/Benserazide Products compared with original Madopar® / Prolopa® POSTER TOURS Poster Tour W9 Margarita Makoutonina AmbuloSono: a sensorimotor contingent musical walking program for people livingwith Parkinson’s disease Neurocognitive rehabilitation with motor imagery vs treadmill training forfreezing of gait in Parkinson’s disease. A randomized controlled study A unique community Group Rehabilitative Exercise and Therapy (GREAT) program forpeople with Parkinson’s disease The effectiveness of occupational therapy in Parkinson’s disease The effect of dopaminergic medication on muscle performance in people with Parkinson’s disease-related fatigue The role of optic flow on locomotion in young adults during overground walking Central components of quadriceps fatigue are dopamine dependent Poster Tour W10 Terry Ellis Impact of freezing of gait on self-perceived balance confidence for functionalactivities in people with Parkinson’s disease Treatment effects of Attention Process Training for an individual with Parkinson’s disease: A single-subject study The impact of high intensity exercise on outcome in people with Parkinson’s disease: A systematic review The type of secondary task matters in dual task walking during the Timed Up and Go Pre-stepping postural preparation in patients with Parkinson’s disease with andwithout freezing of gait Assessment of gait therapy effectiveness in the patients with Parkinson’s disease on the basis of three-dimensional movement analysis Home-based gait improvement in Parkinson’s disease: using video to supportself-cueing Poster Tour W11 Jon Stamford Initial choice of dopaminergic therapy in the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Longitudinal Study-1 (LS-1) Apokyn for morning akinesia trial (AM IMPAKT) A cohort study of Parkinson’s disease in British Columbia Efficacy, safety and tolerability of rasagiline as add-on to suboptimal dopamineagonist monotherapy in Parkinson’s disease (PD): The ANDANTE study Effects of a community-based balance program on enhancing the balance performance in people with Parkinson’s disease Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study) Poster Tour W12 Hayley Carpenter The chain that bonds not binds – a project in awareness Pass the baton for Parkinson’s awareness and fundraising program The social movement: building the More Than Motion™ Facebook community for people living with Parkinson’s disease The effect of Medicare Part D on Parkinson’s disease patients: a four yearretrospective study The accomplishments and challenges of international Parkinson advocacy: socialhistory, literature review and call to action Policy Advocacy on Parkinson’s Diseases in Nepal Parkinson’s UK Research Support Network – working together to find a cure Thursday - October 3, 2013 POSTER TOURS 5:15 PM – 6:45 PM Exhibit Hall (220C)
Presenters of featured posters will be present during poster tours to explain their work. Tours take place at the end of the day onTuesday and Wednesday. Tour sign-up required (see sheets in front of main entrance to Exhibit Hall at 220D). Meeting point at firstposter of tour at 5:15 PM. Poster Tour T1 Guide: Louis Tan Analysis of Gene Expression in Peripheral Blood of Patients with Parkinson’s Disease COMT × DRD4 epistasis impacts cognitive flexibility during the Trail Making Test PARK18 SNP is Associated with Differential Expression of Major Histocompatibility complex II in Healthy Controls and Parkinson’s Disease Patients Investigation of PD brain DNA for SNCA (alpha-synuclein) mutations, and cellular studies of the recently reported H50Q Revisiting Smoking and Parkinson’s: Marker, Cause or Effect? Identification of LRRK2 G2019S modifiers of disease penetrance Lewy body fractions from patients with Parkinson’s disease initiate-synuclein-dependent neurodegeneration in mice and non-human primates Poster Tour T2 Jeffrey Kordower Identification of cis- and trans-regulatory elements and signaling pathways inparkin gene expression — A genomic fugu parkin model Molecular mechanisms of neurodegeneration in the En1+/- mouse model of Parkinson’s disease A reverse engineered Parkinson’s disease gene regulatory network identifies RGS2as a direct modulator of LRRK2 activity Synergistic effects of mGluR5 antagonism and 5-HT1A/1B agonism in a rat model ofL-DOPA-induced dyskinesia Longitudinal in vivo imaging in a novel model of Parkinson’s disease in minipig Parkinsonian features in aging GFAP.HMOX1 transgenic mice overexpressing humanHO-1 in the astroglial compartment LRRK2 G2019S knock in Mice display progressive alterations in dopamine releaseand metabolism Striatal and extrastriatal dopamine correlates with cognition in Lewy bodydisorders: an 11C altropane PET study Poster Tour T3 Mark Guttman In the Clinic, in Education and in the Community: A Capacity Building Strategyfor Comprehensive Supportive Services and Wellness Programs through CommunityPartnership Community wellness for people with Parkinson’s Nutritional status correlates with non-motor and motor symptoms of Parkinson’s disease: A cross-sectional analysis in 143 patients A continous care model: education to rehabilitation to wellness Improving nutritional status in Parkinson’s disease and the effects on Parkinson’s disease symptoms Poster Tour T4 Lucie Lachance Awareness of Parkinson’s Disease Questionnaire (APDQ) in an Urban Asian setting The impact of clinical symptoms on quality of life in patients with advancedstage Parkinson’s disease The Parkinson Atlas: transparency in medical practice variations in PD care in the Netherlands Comparison of the psychological symptoms and disease-specific quality of life (QoL) between early- versus late-onset Parkinson’s disease patients Factors, disabling patients on the early stages of Parkinson’s disease Does home-visiting improve quality of life of those living with Parkinson’s disease living in rural areas? – a program evaluation Patient-centered care in the Parkinson centers of excellence: a multicenter study POSTER TOURS Poster Tour T5 Ruth Hagestuen An evaluation of the Occupational Therapy Memory Group run for those with mildcognitive impairment in Parkinson’s Applying Integrated Chronic Care Management model using LSVT BIG and LSVT LOUD protocol framework for care of people with PD in the home Twenty-five years of discovery: A longitudinal study of Parkinson support groups The effect of a music cue on gait and quality of life in Parkinson’s: a case study Home-based training with Nintendo Wii Fit and Balance Board in Parkinson’s disease. Is it a tool for self-management motor activities in long term care ? Expressive Writing improves Psychosocial Functioning of Patients with Parkinson’s Disease and their Caregivers Poster Tour T6 Laura Marsh The impact of treatment response to cognitive-behavioral therapy on different clusters of depressive symptoms in Parkinson’s Mild Cognitive Impairment in Parkinson’s Disease is linked with ExtensiveCortical Thinning during Longitudinal Analysis Initial Results of a Clinical Trial comparing a Neurocognitive Intervention toSupportive Therapy in Individuals with Parkinson’s Does rTMS enhance memory retention in Parkinson’s Disease (PD)? Working memory and facial expression recognition in Parkinson’s disease individuals Exercise for the mind: Investigating the effects of exercise on cognition in Parkinson’s disease Associations of Cognitive Domain Impairments and Gait in Parkinson’s Disease Poster Tour T7 Thomas Gasser Effect of Dopamine Receptor Binding Agents on Dopamine Transporter (DaT) Scan Result A large Turkish Parkinson Pedigree with alpha-Synuclein Duplication: Blood Expression Biomarkers elucidate predictive Diagnostics and Pathway A Novel Blood-Brain Barrier Permeable PET Ligand for Parkinson’s Disease Longitudinal striatal atrophy during Parkinson’s progression Metabolomic changes associated L-DOPA induced dyskinesia in a MPTP primate modelof Parkinson’s disease and the effect of DHA or plasmalogen precursoradministration Influence of Dopamine Transporter (DaT) scan on medical management in movementdisorders specialists: Cleveland Clinic experience Poster Tour T8 Roger Barker Targeted next-generation sequencing for Parkinson’s disease Case report: transplantation of fetal porcine ventralmesencephalic cells (FPVMC) for Parkinson’s disease (PD): results and pathology Long-term safety considerations of deep brain stimulation in treatment of Parkinson’s disease Modulation of glutamate receptors in dyskinetic MPTP monkeys receiving aunilateral subthalamotomy Social support and motor outcomes after Deep Brain Stimulation in patients with Parkinson’s Disease POSTER TOURS Poster Tour T9 Bastiaan Bloem A novel approach to testing freezing of gait in patients with Parkinson’s disease: The clover test Using the SpeechVive to treat speech impairments in Parkinson’s disease Changes in vowel (co)articulation following intensive voice treatment (LSVT) in Parkinson’s disease The impact of physical environmental barriers on accessibility problems- veryold people with self-reported Parkinson’s disease versus controls Efficacy of mental practice mnemonic coupled with physical practice in improving gait of patients with Parkinson’s disease Development of an intelligent bicycle for rehabilitation in Parkinson’s disease Long-term Observation of Speech and Language in Patients with Parkinson’s Disease under Continuous Levodopa/Carbidopa Intestinal Gel Therapy Poster Tour T10 Marten Munneke Benefits of task-specific learning-principled practice to improve freezing ofgait for individuals with Parkinson disease in a small group community setting. A case series study European physiotherapy guidelines for people with Parkinson’s disease Test-retest and inter-rater reliability of the mini-BESTest in mild to moderate Parkinson’s disease – a clinical approach An acute Parkinson’s therapy pathway; bridging the gap between hospital and home A vision of improved postural stability in Parkinson’s disease: enhancing balance through visual training under dual-task conditions Nicotine and nicotinic receptor drugs reduce L-dopa-induced dyskinesias in anonhuman primate model of Parkinson’s disease Poster Tour T11 Sara Riggare 3D Sensors, the New Paradigm for Assessing Movement Disorders Can single-leg stance time be used to assess bilateral progression of Parkinson’s disease? Dual-task performance assessment (DTPA): A novel test for assessing motor and cognitive performance during dual-task Measures of quality care reveal large variation across NPF Centers of Excellence SENSE-PARK: measuring Parkinson in the home environment in an objective, continuous and minimally obtrusive fashion Poster Tour T12 Israel Robledo Managing Parkinson’s disease symptoms while hospitalized for non-PD related conditions Experiencing Parkinson’s Disease and the Reward System: the point of view of aninformed patient Not only an old person’s disease How the nonprofit sector can help people living with Parkinson’s receive quality voice treatment: two successful models Clinical profile of Parkinson’s disease patients with pneumonia The effect of STN-DBS’s laterality on voice and perception of speechintelligibility of patients with Parkinson’s disease ParkNC: a referral network for enhanced Parkinson’s disease care throughout North Carolina Achieving the impossible together
Inleiding weerstand. De patiënt,drager van het MRSA MRSA infektie in het ziekenhuis Hygiene is afgeleid van het franse woord ‘hygiène’ In een ziekenhuis is kans op besmetting groter als en van het griekse woord ‘hygieinos en betekent gevolg dat mensen door hun ziekte een verlaagde de gezondheid bevorderen.In grote lijnen betekent weerstand hebben en daardoor gevoeliger zijn e
Figure 1. Warfarin Dose Reminder Chart Your doctor has highlighted a row below showing the total amount of warfarin (Coumadin) you should take each week. Look at the highlighted row and find the number under today’s day of the week. Take that number of 5-mg warfarin tablets at approximately 5 p.m. Number of 5-mg tablets to take on each day of the week NOTE TO THE PHYSICIAN: The initial